LYEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lyell Immunopharma Inc (LYEL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish momentum, the lack of recent positive news, poor financial performance, and absence of significant trading signals suggest a cautious approach. Analysts are optimistic about the company's potential, but the financials and stock trend data indicate short-term downside risks. Holding off on investment until more favorable conditions emerge may be prudent.
The technical indicators show mixed signals. The MACD is positive and contracting, suggesting a potential bullish momentum. The RSI is neutral at 49.314, indicating no clear overbought or oversold conditions. Moving averages are bullish with SMA_5 > SMA_20 > SMA_200. However, the stock is trading near a key pivot level of 23.85, with support at 22.749 and resistance at 24.95.
and view the company's lead product, ronde-cel, as a promising CAR-T therapy in a lucrative market. The stock is considered undervalued by analysts.
The company's financial performance is weak, with significant YoY declines in revenue (-45.45%), net income (-26.68%), and EPS (-49.96%). No recent news or significant trading activity from insiders, hedge funds, or congress members. Stock trend analysis indicates a likelihood of short-term downside (-1.97% next day, -2.48% next week).
In 2025/Q4, the company reported a sharp decline in revenue (-45.45% YoY), net income (-26.68% YoY), and EPS (-49.96% YoY). Gross margin remained stable at 100%. Overall, the financials indicate poor growth trends.
Analysts are optimistic about the stock, with Needham, Lucid Capital, and Citizens issuing Buy or Outperform ratings and price targets ranging from $34 to $44. Analysts highlight the company's innovative CAR-T therapy and undervalued assets as key strengths.
